Corticosteroid Use in Otolaryngology: Current Considerations During the COVID-19 Era.
C W David ChangEdward D McCoulSelena E BriggsElizabeth A GuardianiMarlene L DurandTessa A HadlockAlexander T HillelNrusheel KattarPeter J M OpenshawNosayaba Osazuwa-PetersDavid M PoetkerJennifer J ShinSujana S ChandrasekharCarol R BradfordMichael J BrennerPublished in: Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2021)
SCS use for SSNHL, Bell's palsy, laryngotracheal edema, and perioperative care should follow prepandemic standards. Local or topical corticosteroids are preferable for most other otolaryngologic indications. Whether SCSs attenuate response to vaccination against COVID-19 or increase susceptibility to SARS-CoV-2 infection is unknown. Immunosuppression may lower vaccine efficacy, so immunocompromised patients should adhere to recommended infection control practices. COVID-19 vaccination with Pfizer-BioNTech, Moderna, or Johnson & Johnson vaccines is safe for immunocompromised patients.